Update on STELFONTA^® Supply and Distribution Arrangements

BRISBANE, 27 February 2026

QBiotics Group Limited (QBiotics) announces that the Supply and Distribution agreement with Virbac will not be renewed for a second term. QBiotics remains confident in the evolving global opportunity for STELFONTA^® and is exploring new partnerships aligned with the company’s commercial strategy. Importantly, the relationship between QBiotics and Virbac remains strong, and both parties are working collaboratively and constructively through this transition.

QBiotics is committed to supporting the veterinary community and maintaining uninterrupted access for veterinarians and pet owners who choose STELFONTA to treat their dog’s mast cell tumours. QBiotics and Virbac are working closely together to finalise a transition plan that supports the ongoing supply of STELFONTA in the market. As part of this process, Virbac has issued a purchase order for a further 5,000 vials of STELFONTA, with delivery scheduled for 1 May 2026.

STELFONTA is an approved veterinary pharmaceutical in the United States, the European Union, the United Kingdom, Switzerland and Australia, and the Company is actively evaluating alternative commercial and distribution pathways consistent with its broader growth strategy.

Ebru Davidson, QBiotics' Interim Chief Executive Officer commented, "We are grateful for our constructive and collaborative relationship with Virbac, which remains very positive, and we appreciate their ongoing partnership as we work together to ensure continuity of supply for veterinarians and the pet owners and families who depend on this product.

We are energised by the opportunities ahead and confident in our ability to build on STELFONTA’s international foundation while continuing to deliver value for our stakeholders."

QBiotics does not expect the non‑renewal to have a material financial or operational impact on the business. The STELFONTA trademarks, branding and stelfonta.com website continue to be owned by QBiotics, consistent with the Company’s established product portfolio and the Company retains the flexibility to onboard a new marketing and distribution partner or manage distribution directly if required. The non‑renewal is not related to the safety, efficacy, regulatory status, manufacturing quality, or underlying technology of STELFONTA, all of which remain robust and unchanged.

—ends—
 

FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO AND MANAGING DIRECTOR
communications@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
NOTES FOR EDITORS

ABOUT QBIOTICS

QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.

QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. In a Phase II soft tissue sarcoma study the drug delivered an injected tumour Objective Response Rate (ORR) of 80%, with no serious Adverse Events, and translational research validating immunological responses. A Phase II study in head & neck cancer is soon to be reported and impressive safety and efficacy outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I/IIa safety study and efficacy reported for nine different tumour types.

QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human clinical Phase I/IIa study treating Venous Leg Ulcers.

Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of the drug secured for both programmes.

QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complimented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, and translational drug development.

QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.